When can a patient anticipate ipratropium’s onset of action?

Choice A reason: Metronidazole is effective against anaerobic bacteria and protozoa, not gram-positive organisms like MRSA. It targets microbial DNA but lacks activity against Staphylococcus aureus, making it inappropriate for treating MRSA infections, which require antibiotics with specific gram-positive coverage.

Choice B reason: Vancomycin is a first-line treatment for MRSA infections. It inhibits cell wall synthesis by binding to peptidoglycan precursors, effective against gram-positive bacteria like MRSA. Its efficacy in multidrug-resistant infections makes it the preferred choice for serious infections like pressure ulcers in hospitalized patients.

Choice C reason: Tobramycin, an aminoglycoside, targets gram-negative bacteria and is not effective against MRSA, a gram-positive organism. Its spectrum includes Pseudomonas but not resistant Staphylococcus, making it unsuitable for treating MRSA pressure ulcers, which require vancomycin or similar agents.

Choice D reason: Ciprofloxacin, a fluoroquinolone, has some activity against gram-positive bacteria but is not a first-line choice for MRSA due to variable resistance. Vancomycin is more reliable for multidrug-resistant Staphylococcus aureus, especially in serious infections like pressure ulcers, making this an incorrect choice.

Choice A reason: Antiviral drugs are not solely for palliative care. They inhibit viral replication, reducing viral load and disease severity, as with acyclovir for herpes. While some provide symptomatic relief, many target specific viral processes, aiming for virologic suppression or cure, not just palliation.

Choice B reason: Antiviral drugs, like acyclovir, inhibit viral replication (e.g., DNA polymerase), but some, like chemotherapy agents, can affect healthy cells with high turnover, causing side effects like myelosuppression. This non-specificity is a key consideration, as it limits dosing and requires monitoring for toxicity.

Choice C reason: Antiviral efficacy does not depend on avoiding re-exposure. Drugs like oseltamivir reduce viral replication during active infection, but re-exposure may cause new infections. Prophylaxis or vaccination prevents reinfection, not the drug’s initial effectiveness, making this statement incorrect for antiviral therapy.

Choice D reason: Antivirals cannot be dosed to eradicate viruses without harming healthy cells. Their mechanisms, like inhibiting viral enzymes, often affect host cells, causing toxicity (e.g., nephrotoxicity with acyclovir). Dose limitations balance efficacy and safety, preventing complete viral eradication without side effects.